Biogen Inc.

ticker: BIIB step: 01 generated: 2026-05-12 source: quick-research

Biogen Inc. (BIIB) — Business Overview

Business Description

Biogen is a pioneering biotechnology company focused on neurological diseases, founded in 1978 and headquartered in Cambridge, Massachusetts. The company is in a critical transition: its legacy multiple sclerosis (MS) franchise (historically ~60–70% of revenue) is in structural decline as branded drugs face generic competition, while four first-in-class launch products — Leqembi (Alzheimer's), Skyclarys (Friedreich's ataxia), Zurzuvae (postpartum depression), and Qalsody (ALS) — are building toward a new revenue base. Leqembi, developed in partnership with Eisai, is the first disease-modifying Alzheimer's treatment to demonstrate meaningful clinical benefit and represents Biogen's most important strategic asset for the next decade.

Revenue Model

Biogen generates revenue through three channels: (1) Product sales (~85% of revenue): branded MS therapies (Tysabri, Avonex, Plegridy), SMA drug Spinraza, and four new launch products (Leqembi, Skyclarys, Zurzuvae, Qalsody); (2) Collaboration revenue (~10%): royalties from Roche's Ocrevus (CD20 therapy, $7B+ in annual sales; Biogen receives ~13% royalty) and other partnership agreements; (3) Other revenue (~5%): contract manufacturing, milestone payments. The company is executing a $1B gross savings program ($800M net) to offset the MS revenue decline and fund new product investment.

Products & Services

• Multiple Sclerosis (Legacy): Tecfidera (biosimilar competition), Tysabri, Avonex, Plegridy, Fampyra — collectively declining ~10–15% annually
• SMA: Spinraza (intrathecal antisense oligonucleotide) — competing with Zolgensma (Novartis gene therapy) and Risdiplam (Roche)
• Alzheimer's (Growth): Leqembi (lecanemab-irmb) — anti-amyloid IV infusion; subcutaneous autoinjector under FDA priority review for home administration; co-promoted globally with Eisai
• Rare Neurological (Growth): Skyclarys (omaveloxolone) — first approved treatment for Friedreich's ataxia; acquired via Reata Pharmaceuticals ($7.3B, 2023)
• Depression (Growth): Zurzuvae (zuranolone) — first pill for postpartum depression; partnered with Sage Therapeutics
• ALS (Growth): Qalsody (tofersen) — antisense therapy for SOD1-ALS; orphan disease
• Pipeline: Six Phase III candidates including felzartamab (IgA nephropathy), multiple neurology programs

Customer Base & Go-to-Market

Biogen sells to hospitals, specialty pharmacies, neurology clinics, and Alzheimer's treatment centers globally through a specialty sales force. Leqembi is distributed through an authorized treatment center network — infusion centers with PET scan or CSF biomarker testing capability are required for diagnosis confirmation. The subcutaneous autoinjector (under FDA review) would significantly expand patient access by enabling home administration. Key payer relationships (Medicare, commercial insurers) drive coverage and access.

Competitive Position

Biogen is one of the pioneers of modern biotechnology but faces significant competitive pressure across its legacy portfolio. In MS, generic Tecfidera entry significantly eroded revenue. In SMA, Spinraza faces strong competition from Novartis' Zolgensma (gene therapy, one-time cure) and Roche's risdiplam (oral pill). In Alzheimer's, Leqembi holds ~60% market share in the anti-amyloid segment but competes with Eli Lilly's Kisunla (donanemab). Biogen's moat in neuroscience comes from decades of CNS biology expertise, deep neurologist relationships, and a first-mover position in Alzheimer's disease-modification.

Key Facts

• Founded: 1978
• Headquarters: Cambridge, Massachusetts
• Employees: ~6,000 (post-restructuring; reduced from ~9,000+)
• Exchange: NASDAQ
• Sector / Industry: Health Care / Biotechnology
• Market Cap: ~$20–25B (trading at historically depressed multiples vs. pipeline potential)

ticker: BIIB step: 04 generated: 2026-05-12 source: quick-research

Biogen Inc. (BIIB) — Financial Snapshot

Income Statement Summary

FY2025: Revenue ~$9.9B (+2%); non-GAAP EPS growth continuing. GAAP volatility reflects one-time charges (Reata acquisition amortization, restructuring costs). Non-GAAP EPS is the most relevant operational metric. GAAP FY2023 decline reflects $6.5B+ in Reata acquisition-related charges.

Cash Flow & Balance Sheet (FY2024)

FCF yield of ~11–16% at current market cap is exceptionally high for a large-cap biotech, reflecting the market's skepticism about Leqembi's commercial trajectory.

Key Ratios (approximate, FY2024)

• P/E (non-GAAP): ~10–13x | FCF Yield: ~11–16%
• EV/EBITDA: ~8–10x | Dividend: None
• Revenue Growth (FY2024): -1.6% | FCF Margin: ~28%
• Ocrevus Royalty (~$700–800M/year): High-margin, declining as new CD20 competitors emerge

Growth Profile

Biogen's financials are a study in transition: the MS franchise that drove $10B+ in peak revenue is declining at 10–15% annually, partially offset by growing new product revenues. The four launch products (Leqembi, Skyclarys, Zurzuvae, Qalsody) grew 67% YoY in FY2024 — but from a small base. Leqembi global in-market sales reached $134M in Q4 2025 — growing 54% YoY. Annualizing Q4 2025 implies ~$500-600M in run-rate Leqembi sales entering 2026. If the subcutaneous autoinjector is approved (FDA priority review), home administration could dramatically expand the eligible patient population.

Forward Estimates

• FY2025/FY2026: Revenue stabilization ~$9.5–$10.0B as Leqembi ramps; non-GAAP EPS ~$16–18
• Leqembi peak potential: Analyst estimates range from $2–10B in annual global sales; Jefferies is a notable bull citing home injection expansion; bears point to APOE4 subgroup limitations
• Cost discipline: $800M net savings program reduces operating expenses; improving margins despite revenue headwinds
• Reata amortization: Ongoing drag on GAAP EPS ($6.5B acquisition amortized over product life); non-GAAP excludes this